(Q34807126)

4 August 2017

title

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience (English)

1 reference

4 August 2017

1 reference

14

L W M M Terstappen

1 reference

4 August 2017

D Olmos

1

1 reference

4 August 2017

H-T Arkenau

2

1 reference

4 August 2017

J E Ang

3

1 reference

4 August 2017

I Ledaki

4

1 reference

4 August 2017

G Attard

5

1 reference

4 August 2017

C P Carden

6

1 reference

4 August 2017

A H M Reid

7

1 reference

4 August 2017

R A'Hern

8

1 reference

4 August 2017

P C Fong

9

1 reference

4 August 2017

N B Oomen

10

1 reference

4 August 2017

R Molife

11

1 reference

4 August 2017

D Dearnaley

12

1 reference

4 August 2017

C Parker

13

1 reference

4 August 2017

J S de Bono

15

1 reference

4 August 2017

publication date

11 August 2008

1 reference

4 August 2017

1 reference

4 August 2017

volume

20

1 reference

4 August 2017

issue

1

1 reference

4 August 2017

page(s)

27-33

1 reference

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN544

Prostate cancer clinical trial end points: "RECIST"ing a step backwards.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN544

Clinical trials in relapsed prostate cancer: defining the target

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN544

Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN544

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN544

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN544

Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN544

Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN544

Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN544

Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN544

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDN544

1 reference

4 August 2017

1 reference